TEAMIT RESEARCH SL

Their core work

TEAMIT Research is a Barcelona-based SME specializing in health data infrastructure, clinical trial design, and outcomes research for the pharmaceutical and public health sectors. They build data collection systems, common data models, and analytical frameworks that enable large-scale epidemiological studies and patient-centric clinical trials across Europe. Their work spans RSV disease surveillance, platform trial operations using Bayesian statistics, patient-reported outcomes systems, and environmental risk assessment of pharmaceuticals. They serve as a technical backbone for multi-country health research consortia, providing the data architecture and research methodology that ties large collaborative projects together.

What they specialise in

How they've shifted over time

TEAMIT's early H2020 work (2017-2019) centered on infectious disease epidemiology — specifically RSV surveillance, burden-of-disease studies, biobank development, and clinical trial methodology including Bayesian statistics. From 2020 onward, their focus broadened significantly into patient-centric outcomes research (patient-reported outcomes, common data models, value-based healthcare) and unexpectedly into environmental pharmaceutical assessment. This evolution suggests a company moving from disease-specific data work toward becoming a broader health data infrastructure provider, with a growing interest in how medicines impact both patients and the environment.

TEAMIT is transitioning from disease-specific epidemiological research toward cross-cutting health data platforms and outcomes measurement, positioning them as a versatile partner for any consortium needing robust patient data infrastructure.

How they like to work

TEAMIT operates exclusively as a consortium participant — across all six projects, they have never served as coordinator, which points to a specialist-contributor model rather than a project leadership role. However, their average funding of EUR 520K per project is substantial for an SME participant, indicating they carry significant work packages rather than playing marginal roles. With 112 unique partners across 17 countries, they clearly thrive in large IMI-style and RIA consortia and bring a wide collaborative network, making them easy to integrate into new partnerships.

TEAMIT has collaborated with 112 distinct partners across 17 countries, reflecting deep integration into Europe's health research ecosystem. Their involvement in IMI2 projects (public-private partnerships with major pharmaceutical companies) gives them connections across both academic and industry networks.

What sets them apart

TEAMIT occupies a distinctive niche as an SME that bridges epidemiological research and health data engineering. Unlike academic partners who focus on scientific questions, or large CROs that manage trial logistics, TEAMIT specializes in the data architecture layer — building the common data models, outcome measurement systems, and governance frameworks that make multi-country health studies actually work. Their rare combination of RSV disease expertise with patient outcomes methodology and environmental pharmaceutical assessment makes them unusually versatile for a company of their size.

Highlights from their portfolio

• EU-PEARL
  Their largest grant (EUR 985K) for building a patient-centric clinical trial platform using Bayesian adaptive designs across multiple disease areas — a flagship IMI2 initiative.
• H2O
  Health Outcomes Observatory (EUR 666K) is building a pan-European patient-reported outcomes infrastructure with common data models — directly aligned with the EU push toward value-based healthcare.
• PREMIER
  Unusual diversification into environmental pharmaceutical risk — ecotoxicology and greener drug design represents a strategic expansion beyond traditional clinical research.